{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:01:21Z","timestamp":1790704881623,"version":"4.1.0"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T00:00:00Z","timestamp":1373500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0002309","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T20:48:01Z","timestamp":1373575681000},"page":"e2309","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":51,"title":["A Single Immunization with MVA Expressing GnGc Glycoproteins Promotes Epitope-specific CD8+-T Cell Activation and Protects Immune-competent Mice against a Lethal RVFV Infection"],"prefix":"10.1371","volume":"7","author":[{"given":"Elena","family":"L\u00f3pez-Gil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Hevia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Groschup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,7,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1051\/vetres\/2010033","article-title":"Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention","volume":"41","author":"M Pepin","year":"2010","journal-title":"Vet Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S0022172400062434","article-title":"Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an inter-epizootic period in Kenya","volume":"95","author":"KJ Linthicum","year":"1985","journal-title":"J Hyg (Lond)"},{"key":"ref3","first-page":"514","article-title":"Rift valley fever in South Africa; a study of the 1953 outbreak in the Orange Free State, with special reference to the vectors and possible reservoir hosts","volume":"29","author":"J Gear","year":"1955","journal-title":"S Afr Med J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0035-9203(78)90134-7","article-title":"Rift Valley Fever virus infections in Egypt: Pathological and virological findings in man","volume":"72","author":"KS Abdel-Wahab","year":"1978","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(87)92110-6","article-title":"Focus of Rift Valley fever virus transmission in southern Mauritania","volume":"1","author":"JF Saluzzo","year":"1987","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0140-6736(05)61043-4","article-title":"Origin of 1997\u201398 Rift Valley fever outbreak in East Africa","volume":"352","author":"AA Sall","year":"1998","journal-title":"Lancet"},{"key":"ref7","first-page":"73","article-title":"Rift Valley fever outbreak\u2013Kenya, November 2006\u2013January 2007","volume":"56","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4269\/ajtmh.2010.09-0292","article-title":"Rift Valley fever outbreak in livestock in Kenya, 2006\u20132007","volume":"83","author":"P Munyua","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(05)74068-X","article-title":"More deaths from Rift Valley fever in Saudi Arabia and Yemen","volume":"356","author":"K Ahmad","year":"2000","journal-title":"Lancet"},{"key":"ref10","first-page":"157","article-title":"Outbreak news. Rift Valley fever, Madagascar","volume":"83","journal-title":"Wkly Epidemiol Rec"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3201\/eid1504.081045","article-title":"Rift Valley fever, Mayotte, 2007\u20132008","volume":"15","author":"D Sissoko","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3201\/eid1606.091266","article-title":"Rift Valley fever during rainy seasons, Madagascar, 2008 and 2009","volume":"16","author":"SF Andriamandimby","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3201\/eid1707.102031","article-title":"Rift valley Fever in ruminants, republic of comoros, 2009","volume":"17","author":"M Roger","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"19506","DOI":"10.2807\/ese.15.10.19506-en","article-title":"Rift Valley fever\u2013a threat for Europe?","volume":"15","author":"V Chevalier","year":"2010","journal-title":"Euro Surveill"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"D69","DOI":"10.1016\/j.vaccine.2009.07.046","article-title":"Rift valley fever vaccines","volume":"27 Suppl 4","author":"T Ikegami","year":"2009","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1128\/JVI.02641-10","article-title":"Rift valley fever: recent insights into pathogenesis and prevention","volume":"85","author":"H Boshra","year":"2011","journal-title":"J Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.coviro.2012.02.017","article-title":"Breaking the chain: Rift Valley fever virus control via livestock vaccination","volume":"2","author":"BH Bird","year":"2012","journal-title":"Curr Opin Virol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","article-title":"Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep","volume":"28","author":"B Dungu","year":"2010","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: past, present and future","volume":"84","author":"BL Jacobs","year":"2009","journal-title":"Antiviral Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652311795684731","article-title":"MVA and NYVAC as vaccines against emergent infectious diseases and cancer","volume":"11","author":"CE Gomez","year":"2011","journal-title":"Curr Gene Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/156652308784049363","article-title":"The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer","volume":"8","author":"CE Gomez","year":"2008","journal-title":"Curr Gene Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.vaccine.2005.12.041","article-title":"A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S\/AS02A and MVA-CS","volume":"24","author":"SJ Dunachie","year":"2006","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1479-5876-7-2","article-title":"Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma","volume":"7","author":"HL Kaufman","year":"2009","journal-title":"J Transl Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"RJ Amato","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"TK Berthoud","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e13983","DOI":"10.1371\/journal.pone.0013983","article-title":"Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate","volume":"5","author":"JR Currier","year":"2010","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1016\/j.vaccine.2011.08.098","article-title":"Safety and immunogenicity of a modified pox vector-based HIV\/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)","volume":"29","author":"F Garcia","year":"2011","journal-title":"Vaccine"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles","volume":"203","author":"PA Goepfert","year":"2011","journal-title":"J Infect Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/1042819031000149368","article-title":"Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation","volume":"45","author":"DF Tough","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.4049\/jimmunol.176.8.4682","article-title":"Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming","volume":"176","author":"A Le Bon","year":"2006","journal-title":"J Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus","volume":"24","author":"K Spik","year":"2006","journal-title":"Vaccine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs","volume":"6","author":"N Lagerqvist","year":"2009","journal-title":"Virol J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"DB Wallace","year":"2006","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e9015","DOI":"10.1371\/journal.pone.0009015","article-title":"Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses","volume":"5","author":"RA Koup","year":"2010","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1473-3099(11)70240-7","article-title":"DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials","volume":"11","author":"JE Ledgerwood","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-\/-) mice induced by different DNA vaccination regimens","volume":"28","author":"G Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1016\/j.vaccine.2008.07.042","article-title":"Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep","volume":"26","author":"G Lorenzo","year":"2008","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1286-4579(00)01323-X","article-title":"Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85","volume":"2","author":"AS Malin","year":"2000","journal-title":"Microbes Infect"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1128\/IAI.69.2.681-686.2001","article-title":"Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis","volume":"69","author":"H McShane","year":"2001","journal-title":"Infect Immun"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4161\/mabs.2.3.11676","article-title":"Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization","volume":"2","author":"R Martin-Folgar","year":"2010","journal-title":"MAbs"},{"key":"ref41","first-page":"45","article-title":"An inactivated rift valley fever vaccine","volume":"48","author":"BJ Barnard","year":"1977","journal-title":"J S Afr Vet Assoc"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1371\/journal.pntd.0000725","article-title":"Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus","volume":"4","author":"N Bhardwaj","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1002\/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P","article-title":"Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use","volume":"28","author":"M Plebanski","year":"1998","journal-title":"Eur J Immunol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.4049\/jimmunol.158.5.2278","article-title":"Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization","volume":"158","author":"DM Feltquate","year":"1997","journal-title":"J Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0264-410X(97)00226-0","article-title":"Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime\/MVA boost vaccination regime","volume":"16","author":"T Hanke","year":"1998","journal-title":"Vaccine"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1016\/S0264-410X(01)00260-2","article-title":"A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees","volume":"19","author":"J Schneider","year":"2001","journal-title":"Vaccine"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e25027","DOI":"10.1371\/journal.pone.0025027","article-title":"Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice","volume":"6","author":"P Jansen van Vuren","year":"2011","journal-title":"PLoS One"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.4049\/jimmunol.1003057","article-title":"LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus","volume":"186","journal-title":"J Immunol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1016\/j.vaccine.2011.04.043","article-title":"A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-\/-) mice upon lethal virus challenge","volume":"29","author":"H Boshra","year":"2011","journal-title":"Vaccine"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e59210","DOI":"10.1371\/journal.pone.0059210","article-title":"The nucleocapsid protein of rift valley Fever virus is a potent human CD8(+) T cell antigen and elicits memory responses","volume":"8","author":"W Xu","year":"2013","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"14926","DOI":"10.1073\/pnas.1112149108","article-title":"Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice","volume":"108","author":"JF Papin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"12102","DOI":"10.1128\/JVI.01190-07","article-title":"Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses","volume":"81","author":"Z Waibler","year":"2007","journal-title":"J Virol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/JVI.01617-08","article-title":"Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components","volume":"83","author":"Z Waibler","year":"2009","journal-title":"J Virol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"S Hervas-Stubbs","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"e1002407","DOI":"10.1371\/journal.ppat.1002407","article-title":"A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection","volume":"7","author":"AK Pinto","year":"2011","journal-title":"PLoS Pathog"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4049\/jimmunol.174.1.99","article-title":"Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells","volume":"174","author":"N Dikopoulos","year":"2005","journal-title":"J Immunol"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0002309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T02:48:19Z","timestamp":1688352499000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0002309"}},"subtitle":[],"editor":[{"given":"Brian","family":"Bird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,11]]},"references-count":56,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0002309","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,11]]}}}